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Abstract
Background:  Late-life depression is a common, chronic and recurring disorder for which
guidelines recommend long-term therapy. The safety and efficacy of duloxetine for the treatment
of major depressive disorder (MDD) were evaluated using data from elderly patients (age ≥ 65
years; n = 101) who participated in a large, multinational, open-label study.
Methods: Patients meeting DSM-IV criteria for MDD received duloxetine 80 mg/d (40 mg twice
daily (BID)) to 120 mg/d (60 mg BID) for up to 52 weeks. Efficacy measures included the Clinical
Global Impression of Severity (CGI-S) scale, the 17-item Hamilton Rating Scale for Depression
(HAMD17), the Beck Depression Inventory-II (BDI-II), the Patient Global Impression of
Improvement (PGI-I) scale, and the Sheehan Disability Scale (SDS). Safety and tolerability were
evaluated using discontinuation rates, spontaneously reported adverse events, and changes in vital
signs, ECG, and laboratory analytes.
Results: Mean changes in HAMD17 total score at Weeks 6, 28, and 52 were -13.0, -17.4 and -17.5
(all p-values <.001). Significant improvement (p < .001) in both clinician- (CGI-S) and patient-rated
(PGI-I) measures of improvement were observed at Week 1 and sustained throughout the study.
Observed case response rates at Weeks 6, 28, and 52 were 62.9%, 84.9%, and 89.4%, respectively,
while the corresponding rates of remission were 41.4%, 69.8%, and 72.3%. Adverse events led to
discontinuation in 27 (26.7%) patients. Treatment-emergent adverse events reported by >10% of
patients included dizziness, nausea, constipation, somnolence, insomnia, dry mouth, and diarrhea.
Most events occurred early in the study. Mean changes at endpoint in blood pressure and body
weight were less than 2.0 mm Hg, and -0.1 kg, respectively.
Conclusions: In this open-label study, duloxetine was effective, safe, and well tolerated in the long-
term treatment of MDD in patients aged 65 and older.
Background
Late-life depression is a common and disabling condition
which represents a substantial public health concern [1].
The prevalence of major depressive disorder (MDD) in the
community-dwelling elderly population is estimated at
1–3%, with depressive symptoms being present in
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approximately 15% [2]. The rate of occurrence of MDD is
even higher among institutionalized older patients. In
long-term care patients the incidence has been estimated
to be 12% to 25%, with subsyndromal depressive symp-
toms present in an additional 18% to 30% [3].
Despite advances in available antidepressant treatments,
limitations still exist in both efficacy and safety. Tricyclic
antidepressants (TCAs) generally provide robust efficacy,
but a number of side effects associated with this class of
medications are of particular concern in older patients
(e.g. anticholinergic adverse events, orthostatic hypoten-
sion, and sedation). Selective serotonin reuptake inhibi-
tors (SSRIs) have provided an improved tolerability
profile compared to the TCAs through lower rates of
adverse events, and substantially lower toxicity in over-
dose [4]. Furthermore, SSRIs do not appear to exhibit age-
related increases in occurrence of adverse events [5]. How-
ever, these newer selective antidepressants appear, in gen-
eral, to achieve equivalent or lower remission rates
compared with the older tricyclics [6].
Duloxetine is a potent dual reuptake inhibitor of serot-
onin (5-HT) and norepinephrine (NE) [7]. The efficacy of
duloxetine in the acute treatment of MDD has been estab-
lished in randomized, double-blind, placebo-controlled
studies in patients aged 18 and older [8-11]. A subsequent
post-hoc analysis of efficacy data from these studies,
focusing upon those patients aged 55 and older receiving
once-daily duloxetine (60 mg), supported the findings in
the general patient population [12].
The safety and tolerability of duloxetine have also been
demonstrated under double-blind conditions. In placebo-
controlled trials of duloxetine in patients aged 18 and
older (doses from 40 – 120 mg/d) the most frequently
reported adverse events were nausea, headache, dry
mouth, fatigue, insomnia, and dizziness, while the overall
safety profile of duloxetine was comparable to that of
available SSRI medications [11]. A comparable safety and
tolerability profile was observed following a post-hoc
analysis of data from those patients aged 55 and older,
including a low incidence of cardiovascular adverse events
and minimal effects upon blood pressure and heart rate
[12].
However, these acute placebo-controlled trials of duloxe-
tine were of 9 weeks duration or less. An NIH consensus
panel has recommended that geriatric patients be given
continuing antidepressant treatment for at least 6 months
for a first episode and for at least 1 year for recurrent epi-
sodes [13], while some investigators suggest that mainte-
nance treatment in the elderly be extended to 2 years [14].
In order to evaluate the long-term tolerability, safety, and
efficacy of duloxetine, a one-year open-label trial in
depressed patients was undertaken. This report examines
the subset of patients aged 65 and older who participated
in the study. While patients in this study received doses of
80 mg/d or 120 mg/d, it should be noted that the
approved dose range for duloxetine for the treatment of
MDD is 40–60 mg/d.
Methods
Study design
This was a 52-week, open-label, single-arm study of out-
patients (aged ≥ 18 years) meeting Diagnostic and Statisti-
cal Manual of Mental Disorders, 4th Edition (DSM-IV) [15]
criteria for MDD. The study included a total of 1279
patients at 52 investigative sites in Argentina, Brazil, Can-
ada, Columbia, Mexico, the United States, and Venezuela.
The primary objective of the study was to evaluate the
safety of duloxetine (80 or 120 mg/d given as two equal
doses per day, i.e. 40 to 60 mg BID) for up to 52 weeks.
During the first week of therapy, all patients received
duloxetine 40 mg BID. Patients unable to tolerate 40 mg
BID could have their dose decreased to 20 mg BID, but
were required to increase the dose to 40 mg BID at Week
2. Patients unable to tolerate 40 mg BID were discontin-
ued from the study. During the remainder of the study,
the patient's dose could be adjusted up to 60 mg BID or
down to 40 mg BID, based upon the physician's clinical
evaluation of tolerability and efficacy.
This report focuses upon data taken from the subset of
patients aged 65 years and older (n = 101) within the
larger study described above.
Patients
The study protocol was approved by the ethics committee
at each site in accordance with the principles of the Decla-
ration of Helsinki. All patients provided written informed
consent prior to the administration of any study proce-
dures or study drug. All patients were required to have a
Clinical Global Impression of Severity (CGI-S) score ≥ 3 at
the screening and baseline study visits.
Patients were excluded for the following reasons: a previ-
ous or current diagnosis of schizophrenia, schizophreni-
form disorder, schizoaffective disorder, or bipolar
disorder; presence of an Axis II disorder that would inter-
fere with protocol compliance; serious medical illness;
taking benzodiazepines on a daily basis for ≥ 2 weeks
prior to enrollment; a history of substance dependence
within the last year; or a positive urine drug screen. Sub-
jects judged to be at risk for suicide were also excluded.
Concomitant medications
Patients were not permitted to receive other antidepres-
sant, antimanic, or antipsychotic agents during the study.
Episodic use (≤ 3 consecutive days, and no more than 100BMC Geriatrics 2004, 4:11 http://www.biomedcentral.com/1471-2318/4/11
Page 3 of 10
(page number not for citation purposes)
total days) of benzodiazepines was permitted. The use of
benadryl, chloral hydrate, cough and cold medications,
and narcotics, was allowed on an episodic basis only. Sub-
jects were permitted to take antihypertensives,
antiarrhythmics, antibiotics, and multivitamins among
other medications while in the study.
Efficacy measures
Efficacy was assessed using the CGI-S scale [16] (a priori
specified as the primary outcome), the HAMD17 total
score [17], HAMD17 subscales (core – Items 1, 2, 3, 7, and
8; Maier – Items 1, 2, 7, 8, 9, and 10; anxiety/somatization
– Items 10, 11, 12, 13, 15, and 17; retardation – Items 1,
7, 8, and 14; sleep – Items 4, 5, and 6), the Beck Depres-
sion Inventory-II (BDI-II) [18], and the Patient Global
Impression of Improvement (PGI-I) scale [16]. Patient-
rated quality of life was evaluated using the Sheehan Dis-
ability Scale (SDS) [19], which is a composite of 3 self-
rated 10-point Likert response subscales (0 = no disability,
1–3 = mild, 4–6 = moderate, 7–9 = marked, 10 = extreme)
to assess work, family, and social functioning during the
past month. All outcomes were assessed at Weeks 6, 28,
and 52, or upon early discontinuation, except for PGI-I
and CGI-S scales which were collected at all visits. Patients
were defined as responders  if they had a decrease from
baseline of at least 50% in HAMD17 total score. Patients
were defined as remitters if they had a HAMD17 total score
≤ 7.
Safety measures
Safety measures included spontaneously reported adverse
events, serious adverse events (events that led to outcome
of death, inpatient hospitalization, cancer, severe or per-
manent disability, congenital abnormality, or life-threat-
ening condition), vital signs, electrocardiograms (ECGs),
and laboratory analyses. Adverse events and vital signs
were collected at each visit.
Lilly reference ranges were used to define limits for abnor-
mal laboratory values [20], and potentially clinically sig-
nificant (PCS) changes in selected laboratory analytes
[21]. PCS changes in blood pressure were defined as
follows:
(i) Low supine (or standing) systolic BP: ≤ 90 mm Hg and
a decrease from baseline of ≥ 20 mm Hg;
(ii) High supine (or standing) systolic BP: ≥ 180 mm Hg
and an increase from baseline of ≥ 20 mm Hg
(iii) Low supine (or standing) diastolic BP: ≤ 50 mm Hg
and a decrease from baseline of ≥ 15 mm Hg;
(iv) High supine (or standing) diastolic BP: ≥ 105 mm Hg
and an increase from baseline of ≥ 15 mm Hg.
Patients were considered hypertensive at baseline if they
had a historical diagnosis, secondary condition, or
adverse event at the baseline visit consistent with a clinical
diagnosis of hypertension or high blood pressure.
ECGs were collected at baseline and Weeks 4, 28, 52 or at
early discontinuation. Patients at 2 sites in Mexico and 1
site in Columbia also had ECGs over-read by a cardiolo-
gist at a central location. For these ECGs, QT intervals
were corrected (QTc) using Fridericia's correction (QTcF).
All other patients had ECGs read by the site for classifica-
tion as either normal or abnormal. Limits for PCS QTc val-
ues were an increase in QTcF of ≥ 30 msec and any
postbaseline value ≥ 450 msec for males or ≥ 470 msec for
females [22].
Statistical analyses
Mean changes from baseline to last observation in labora-
tory analytes, vital signs, and ECG intervals were assessed
using ANOVA with models that included investigator.
Longitudinal mean changes and categorical changes (tem-
poral patterns) were assessed via a likelihood-based
repeated measures approach. Models for mean changes
included investigator, visit, baseline value, and baseline-
by-visit interaction.
Mean change in CGI-S score was compared between
younger (age <65) and elderly (age ≥ 65) patients using
the repeated measures analysis as previously described,
with age group and age group-by-visit interaction added
to the model. Differences between young and elderly
patients in rates of treatment emergent adverse events
were assessed using Fisher's exact test.
Table 1: Summary of patient demographics and psychiatric 
historya
Duloxetine, 80–120 mg/d† 
(n = 101)
Gender, n (%)
Female 72 (71.3)
Male 29 (28.7)
Age, y 71.9 (5.4)
Age range, y 65 – 87
Weight, kg 66.5 (14.5)
Ethnicity, n (%)
Caucasian 43 (42.6)
Hispanic 55 (54.5)
Other 3 (3.0)
Age at onset, y 63.5 (13.3)
Current duration, wks 86.0 (161.0)
Number of previous episodes 1.1 (2.1)
Duration of last episode, wks 57.6 (110.2)
a. Listed as mean (SD) unless otherwise stated.
† Administered as 40 mg BID or 60 mg BIDBMC Geriatrics 2004, 4:11 http://www.biomedcentral.com/1471-2318/4/11
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Results
Patient disposition
This report was based on data from 101 patients aged 65
and older. The oldest patient was 87 years of age, while
the median age was 70. Patient characteristics at baseline
are summarized in Table 1.
Efficacy
Mean changes from baseline for all efficacy outcomes
were highly significant (p < .001, t-test for mean change)
at all assessment times (Table 2). In the case of CGI-S and
PGI-I scales, significant improvements were observed at
Week 1 and at all subsequent visits (p < .001, t-test for
mean). Observed case response rates at Weeks 6, 28, and
52 were 62.9% (44/70), 84.9% (45/53), and 89.4% (42/
47), respectively, while the corresponding rates of remis-
sion were 41.4% (29/70), 69.8% (37/53), and 72.3% (34/
47), respectively.
A comparison of visitwise mean changes in CGI-S score
between elderly patients (age ≥ 65, n = 101) and those
patients in the study aged <65 years (n = 1178; Figure 1)
revealed a somewhat more rapid onset of efficacy in
younger patients, with differences between age groups
being statistically significant at Weeks 2, 3 and 4. At sub-
sequent visits the differences between age groups became
progressively smaller, and mean changes were essentially
equal at the study endpoint.
Treatment discontinuation
The most common reasons for study discontinuation
were adverse event (26.7%), personal conflict/other rea-
sons (9.9%), and noncompliance (5.0%). The adverse
events leading to discontinuation in >1.0% of enrolled
Table 2: Efficacy outcome measures
Outcome measure Mean baseline score Mean change (SE)
Week 6 Week 28 Week 52
CGI-Severity 4.51 -2.08 (0.11)** -2.93 (0.12)** -3.15 (0.12)**
PGI-Improvement N/A 2.33 (0.14)** 1.83 (0.16)** 1.84 (0.16)**
HAMD17 Total Score 21.8 -13.0 (0.7)** -17.4 (0.8)** -17.5 (0.8)**
Anxiety subscale 6.70 -3.46 (0.30)** -4.89 (0.33)** -4.90 (0.34)**
Core subscale 8.83 -5.65 (0.33)** -7.50 (0.36)** -7.61 (0.38)**
Maier subscale 10.7 -6.64 (0.38)** -8.90 (0.42)** -9.06 (0.44)**
Retardation subscale 7.84 -4.49 (0.27)** -6.58 (0.30)** -6.49 (0.31)**
Sleep subscale 3.68 -2.34 (0.21)** -2.84 (0.23)** -2.83 (0.24)**
HAMD17 Item 1 2.64 -1.73 (0.11)** -2.30 (0.13)** -2.30 (0.13)**
HAMD17 Item 3 0.74 -0.58 (0.06)** -0.59 (0.06)** -0.61 (0.06)**
BDI-II Total Score 29.5 -15.8 (1.0)** -22.3 (1.1)** -22.0 (1.1)**
Sheehan Disability 
Scale
Work item 6.91 -3.01 (0.32)** -4.60 (0.37)** -4.27 (0.39)**
Family item 6.82 -3.63 (0.32)** -4.88 (0.35)** -4.95 (0.37)**
Social item 7.27 -3.45 (0.34)** -4.57 (0.38)** -4.85 (0.40)**
** p < .001 from t-test for mean change
CGI-Severity = Clinical Global Impression of Severity; PGI-Improvement = Patient Global Impression of Improvement; HAMD17 = 17-item 
Hamilton Rating Scale for Depression; BDI-II = Beck Depression Inventory-II
Comparison of mean change in CGI-Severity score for  duloxetine-treated patients aged ≥ 65 years (n = 98) and age  18–64 years (n = 1121) Figure 1
Comparison of mean change in CGI-Severity score for 
duloxetine-treated patients aged ≥ 65 years (n = 98) and age 
18–64 years (n = 1121). * p ≤ .05 for between-group 
comparison.
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patients at a duloxetine dose of 80–120 mg/d were som-
nolence (4.0%), dizziness (3.0%), diarrhea (2.0%),
hypertension (2.0%), and vomiting (2.0%). Two-thirds of
the discontinuations due to adverse events (18/27)
occurred within 2 weeks of initiation of therapy.
Serious adverse events
A total of 9 enrolled patients reported serious adverse
events during the study. Most of these events were consid-
ered by the investigator to be unrelated to duloxetine
exposure. The serious adverse events reported by more
than 1 patient were hip fracture (2), and confusion (2),
while there were single reports of agitation, angina pec-
toris, cerebrovascular disorder, coronary artery atheroscle-
rosis, dementia, dizziness, hypomania, and myocardial
ischemia. Individual occurrences were few, thus no clear
temporal pattern of incidence of each event could be
determined.
Treatment-emergent adverse events
Treatment-emergent adverse events occurring in >5% of
patients during the open-label therapy phase (Weeks 1
through 52) are summarized in Table 3. The incidence for
these events during Weeks 1 to 8 and Weeks 9 to 52 are
also listed in Table 3. During Weeks 1 through 52, adverse
events reported by more than 10% of patients were dizzi-
ness, nausea, constipation, somnolence, insomnia, dry
mouth, diarrhea, headache, and increased sweating. Over
75% of occurrences of these events were rated as mild or
moderate in severity. The incidence of treatment-emer-
gent adverse events was lower during the latter 44 weeks
of the study (Weeks 9 to 52) than during the first 8 weeks.
Each event with an incidence of at least 5% during Weeks
9 to 52 was also present at the same or higher rate during
the first 8 weeks.
Rates of occurrence of other adverse events of importance
in an elderly population were low: 2 patients experienced
a fall, while there were single reports of syncope and pos-
tural hypotension. When analyzed by age group, patients
aged 65 and older were found to report a significantly
lower incidence of insomnia and headache than those
patients aged <65 (Table 4). No other significant differ-
ences were observed between age groups.
Cardiovascular profile
Mean changes from baseline to last observation for stand-
ing and supine systolic and diastolic blood pressures were
less than 2 mm Hg and not significantly different from
zero: supine systolic BP -1.5 mm Hg (p = .364), supine
diastolic BP -1.8 mm Hg (p = .141), standing systolic BP -
1.9 mm Hg (p = .269), standing diastolic BP -0.1 mm Hg
(p = .907). Using repeated measures analysis, mean
changes in blood pressure were <4 mm Hg at every visit
from baseline to endpoint.
A mean change analysis was utilized to compare blood
pressure in patients who were hypertensive (n = 40) versus
non-hypertensive (n = 58) at baseline. Baseline hyperten-
sive patients exhibited small mean decreases (<4 mm Hg)
in both standing and supine systolic and diastolic blood
pressures from baseline to endpoint, while patients who
were not hypertensive at baseline demonstrated mean
Table 3: Treatment-emergent adverse events†
Event Weeks 1–8, n (%) Weeks 9–52, n (%) Weeks 1–52, n (%)
Nausea 29 (28.7) 0 (0.0) 29 (28.7)
Dizziness 27 (26.7) 5 (5.0) 31 (30.7)
Somnolence 22 (21.8) 1 (1.0) 23 (22.8)
Constipation 20 (19.8) 5 (5.0) 23 (22.8)
Dry mouth 16 (15.8) 4 (4.0) 18 (17.8)
Insomnia 15 (14.9) 8 (7.9) 22 (21.8)
Headache 11 (10.9) 6 (5.9) 16 (15.8)
Increased sweating 11 (10.9) 4 (4.0) 15 (14.9)
Diarrhea 11 (10.9) 6 (5.9) 17 (16.8)
Tremor 7 (6.9) 2 (2.0) 9 (8.9)
Anxiety NEC 7 (6.9) 3 (3.0) 10 (9.9)
Fatigue 7 (6.9) 4 (4.0) 9 (8.9)
Decreased appetite 7 (6.9) 1 (1.0) 7 (6.9)
Vomiting 7 (6.9) 3 (3.0) 10 (9.9)
Anorexia 6 (5.9) 3 (3.0) 8 (7.9)
Back pain 5 (5.0) 2 (2.0) 6 (5.9)
Abdominal pain upper 4 (4.0) 2 (2.0) 6 (5.9)
† Events with an occurrence > 5% in Weeks 1–52.BMC Geriatrics 2004, 4:11 http://www.biomedcentral.com/1471-2318/4/11
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Table 4: Treatment-emergent adverse events by age group†
N (%)
Event Age 18 – 64 (n = 1178) Age ≥ 65 (n = 101) p-Value
Nausea 406 (34.5) 29 (28.7) .274
Insomnia 378 (32.1) 22 (21.8) .034
Headache 373 (31.7) 16 (15.8) <.001
Somnolence 358 (30.4) 23 (22.8) .114
Dry mouth 282 (23.9) 18 (17.8) .180
Dizziness 267 (22. 7) 31 (30.7) .085
Constipation 250 (21.2) 23 (22.8) .705
Increased sweating 177 (15.0) 15 (14.9) 1.00
Anxiety 176 (14.9) 10 (9.9) .188
Diarrhea 157 (13.3) 17 (16.8) .363
Fatigue 125 (10.6) 9 (8.9) .735
† Events with an occurrence > 10% in Weeks 1–52.
Mean change from baseline to endpoint in blood pressure (mm Hg) for baseline hypertensive and non-hypertensive patients  aged ≥ 65 years receiving duloxetine (80–120 mg/d) Figure 2
Mean change from baseline to endpoint in blood pressure (mm Hg) for baseline hypertensive and non-hypertensive patients 
aged ≥ 65 years receiving duloxetine (80–120 mg/d). p > .10 for all between-group comparisons.
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changes in these same measures of 0.3 to -1.1 mm Hg
(Figure 2).
Mean baseline-to-endpoint increases were observed for
supine pulse (mean change = 1.6 bpm, p = .105) and
standing pulse (mean change = 1.1 bpm, p = .338) but
these values did not differ significantly from zero.
Rates of occurrence of potentially clinically significant
(PCS) values for systolic and diastolic blood pressures
were generally low. The incidence of PCS low standing
systolic blood pressure was 5/96 (5.2%), while all other
assessed blood pressure and pulse readings had inci-
dences of PCS values <2.5%.
There were no significant changes in cardiac intervals
detected by ECG. Mean changes from baseline to last
observation were: PR -3.3 msec (p = .363), QRS -2.5 msec
(p = .420), QT 5.0 msec (p = .730), and QTcF 6.2 msec (p
= .553). No patient experienced a PCS QTcF value during
the course of the study.
Body weight
After 52 weeks of treatment, the mean change in weight
from baseline to last observation was -0.1 kg (p = .741),
while a mean weight change of +0.3 kg was determined
using MMRM analysis (p = .386 for t-test for mean change
at endpoint; Figure 3). Mean changes in weight at early
visits were negative (weight loss), mean changes at inter-
mediate visits were near zero, while mean changes at later
visits were positive (weight gain). A total of 3/98 patients
(3.1%) experienced PCS weight loss while 6/98 (6.1%)
reported a PCS weight gain (PCS weight change is defined
as a change of ≥ 10% of baseline body weight). The 3
patients displaying PCS weight loss had baseline body
mass indices (BMI) of 24.9, 28.5 and 32.1, while those
experiencing weight gain had BMIs at baseline ranging
from 19.9 to 26.7.
Mean change in weight (kg) for duloxetine-treated patients aged ≥ 65 years (dose 80–120 mg/d, n = 98) Figure 3
Mean change in weight (kg) for duloxetine-treated patients aged ≥ 65 years (dose 80–120 mg/d, n = 98). *p ≤ .05 from t-test for 
mean change.
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Laboratory analytes
Statistically significant mean changes were observed in
some laboratory analytes. Despite the statistical
significance, the magnitudes of the mean changes were
generally small and not considered clinically relevant in
light of the low incidence of potentially clinically signifi-
cant (PCS) values.
Discontinuation-emergent adverse events
All patients who proceeded past Week 52 received no
study drug for 2 weeks until Week 54 via abrupt discontin-
uation (no taper). Discontinuation-emergent adverse
events occurring in ≥ 5% of patients were dizziness
(8.9%), anxiety (7.9%), headache (5.0%), and insomnia
(5.0%).
Discussion
The current analysis focused upon 101 depressed patients
aged 65 years and older who received long-term, open-
label treatment with duloxetine (80 mg/d or 120 mg/d).
Efficacy was demonstrated on all assessed outcome
measures, both clinician- and patient-rated. Highly signif-
icant improvements were seen in both patient- and clini-
cian-rated depression and health outcome scales (CGI-S,
HAMD17, BDI-II, PGI-I, SDS) at all visits. By way of com-
parison, significantly greater improvements for duloxet-
ine compared with placebo were observed in HAMD17
total score, HAMD17 subscales and CGI-S score in two 9-
week, placebo-controlled studies of duloxetine (60 mg
once daily (QD)) in patients aged 55 years and older [12].
Onset of efficacy is an important consideration in antide-
pressant trials, but in the absence of a placebo arm it is
especially difficult to define and assess [23]. However, the
significant improvements from baseline in CGI-S and
PGI-I scales at Weeks 1 and 2 are consistent with results
from double-blind, placebo-controlled trials in which
duloxetine demonstrated significant superiority over pla-
cebo as early as Week 1 on core emotional symptoms of
depression (HAMD17  Maier subscale), and global
improvement (CGI-S scale) [8]. It has also been suggested
that treatment response may be slower and/or less robust
in an elderly population compared with a younger cohort
[24]. Indeed, in the present study a more rapid onset of
efficacy was observed in duloxetine-treated patients aged
18–64 when compared with those patients aged ≥ 65.
However, the magnitude of treatment differences between
age groups progressively diminished and was not signifi-
cant at any visit after Week 4. This result may have sub-
stantial clinical relevance for long-term treatment. It
suggests that, although those patients aged 65 and older
may exhibit a somewhat less rapid onset of antidepressant
action than a younger cohort, elderly patients are able to
reach and sustain a level of depressive symptom improve-
ment equal to that observed in younger patients.
In this study, observed case response and remission rates
following 6 weeks of open-label duloxetine therapy
(62.9% and 41.4%, respectively) were comparable to the
response and remission rates (52.8% and 44.1%, respec-
tively) observed in older patients in two 9-week double-
blind, placebo controlled trials of duloxetine (60 mg QD)
[12]. Furthermore, remission rates at 52 weeks in the
present study were only slightly less than response rates
(72.3% and 89.4%, respectively), implying that those
patients who responded had a high probability of achiev-
ing complete symptom resolution. A growing body of evi-
dence suggests that remission, rather than response,
should be the goal of antidepressant treatment [25].
Responders who do not remit may have appreciable resid-
ual symptomatology, and patients with residual symp-
toms have been found to be at higher risk for relapse or
recurrence [26]. Given the high rates of relapse and recur-
rence observed among elderly patients, achievement of
remission assumes an added degree of importance.
In light of the recommendation that elderly patients
receive at least 12–18 months of antidepressant therapy
[27], the long-term safety and tolerability of these medica-
tions are of considerable importance. Duloxetine was
safely administered and well-tolerated in this long-term
study. While the discontinuation rate due to adverse
events (26.7%) was somewhat higher than that observed
in older patients (aged ≥ 55) in two 9-week, placebo-con-
trolled trials of duloxetine 60 mg QD (21.0%), the differ-
ence in these rates suggests that few patients stopped
taking medication during the periods associated with con-
tinuation and maintenance treatment. The discontinua-
tion rate is also comparable to that observed in a 54-week
study of fluoxetine in elderly patients [28], and is only
slightly higher than that obtained from a meta-analysis of
acute-phase (≤ 8 week) trials of SSRIs in elderly patients
(14.3%–22.8%) [29]. Given the one-year duration of this
study, and the administration of duloxetine at the upper
end of its studied dose range (80–120 mg/d) throughout
the trial, the long-term tolerability of duloxetine in elderly
patients appears to be comparable to that of SSRIs.
The incidence and pattern of treatment-emergent adverse
events during Weeks 1 to 8 of this study were generally
similar to those observed in acute-phase, placebo-control-
led trials in older patients [12]. The most frequently
reported adverse events were nausea, dizziness, somno-
lence, constipation, and dry mouth. Most of the events
were either mild or moderate in severity and transient in
nature. During the last 44 weeks of the study, no adverse
event occurred in more than 8% of the patient population
and the incidence of each specific event was generally
lower in the entire period from Weeks 9–52 than in the
initial 8 weeks of the study. Thus, patients who toleratedBMC Geriatrics 2004, 4:11 http://www.biomedcentral.com/1471-2318/4/11
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duloxetine during the early period of the trial were likely
to tolerate long-term dosing.
Administration of medication to elderly patients necessi-
tates consideration of the physiological changes which
accompany aging. Such changes can result in substantial
differences in adverse event profiles between older and
younger patient populations [30]. In this study, compari-
sons between age groups (18–64 years vs. ≥ 65 years) of
the most commonly reported treatment emergent adverse
events revealed significant differences only in the rates of
insomnia and headache. Furthermore, in each of these
cases the higher rates were observed in the younger age
group. In the absence of a placebo control arm these
results must be viewed with an appropriate degree of cau-
tion, but they provide an indication that the adverse event
profile for duloxetine in the elderly may be similar to that
observed in younger patients.
Antidepressants with benign cardiovascular profiles may
be particularly suitable for the treatment of an elderly
population, in which heart disease is more prevalent than
in younger patients [31]. In this study, duloxetine-treated
patients exhibited small (less than 2 mm Hg) mean
changes in blood pressure from baseline to endpoint and
low rates of PCS blood pressure values. Furthermore,
those patients with baseline hypertension demonstrated a
mean decrease in blood pressure compared with normo-
tensive patients. Consistent with the profile of duloxetine
as a NE reuptake inhibitor, small mean increases (less
than 2 bpm) were observed in heart rate. Mean changes in
corrected QT interval were small and not significantly dif-
ferent from zero, suggesting duloxetine did not prolong
QT intervals. Collectively, these data indicate that duloxe-
tine exhibits a favorable cardiovascular profile in elderly
patients.
Weight change is an important consideration in older
patients being treated with antidepressants [32], espe-
cially during long-term treatment. Following 52 weeks of
open-label duloxetine treatment, mean change in weight
from baseline to last observation was -0.1 kg. Repeated
measures analysis was used to derive a longitudinal pro-
file of weight change. This revealed a small (<1 kg)
decrease in weight at early visits, consistent with the
weight change of -0.2 kg observed in older patients in two
9-week acute trials of duloxetine [12]. However, mean
changes at intermediate visits approached zero, while
mean changes at the last 2 visits were positive (weight
gain). A total of 3/98 patients (3.1%) reported a PCS
weight loss while 6/98 (6.1%) reported a PCS weight gain.
By way of comparison, a recent study of weight change
among depressed nursing facility residents aged >65 who
received ≥ 6 months of antidepressant treatment found
rates of clinically important weight loss and weight gain
(defined as ≥ 10% change in body weight or Minimum
Data Set-Plus weight loss or weight gain marker) of 14.7%
and 14.4%, respectively [33].
It is important to consider all of the safety findings
described here in light of the dosing and design require-
ments of the study. The doses used in this open-label
study were up to 2-fold greater than the once-daily 60 mg
duloxetine dose which has been shown to provide robust
efficacy in older patients in placebo-controlled trials [12].
The dosing and other design features of the study (e.g. the
intensive visit schedule) were specifically included to
maximize the probability of uncovering adverse reactions
to duloxetine. Furthermore, no special dosing guidelines
were implemented for these elderly patients. While lower
doses of many antidepressants are recommended in the
elderly [34], especially due to concerns of adverse events
among the TCAs, this can lead to the use of subtherapeutic
doses and corresponding reductions in efficacy [35]. In
this study, however, the comparable adverse event profiles
observed for elderly and younger age groups suggest that
a duloxetine dose which has been shown to provide
robust efficacy may be safely administered in depressed
patients regardless of age. Only in particularly sensitive
elderly patients may dosing adjustments be required.
Conclusions
Results from this open-label study of depressed patients
aged 65 and older suggest that duloxetine is safe and well
tolerated in long-term use. Statistically significant and
clinically relevant improvements in all assessed efficacy
measures were observed at each patient visit. Further-
more, the efficacy and adverse event profile of duloxetine
appears to be comparable in older (age ≥ 65) and younger
patients (age 18–64). These results, together with those
obtained from acute phase, double-blind, placebo-con-
trolled trials, support the efficacy of duloxetine in the
treatment of major depression in older patients.
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